The first 3500 years of aspirin history from its roots - A concise summary.
暂无分享,去创建一个
R. de Caterina | M. Montinari | Sergio Minelli | Raffaele De Caterina | Maria Rosa Montinari | Sergio Minelli
[1] Jane A. Linderbaum,et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2013, Journal of the American College of Cardiology.
[2] C. Ji,et al. Acetylation of human prostaglandin endoperoxide synthase-2 (cyclooxygenase-2) by aspirin. , 1994, The Journal of biological chemistry.
[3] R. Collins,et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. , 2009, Lancet.
[4] C. Patrono,et al. Antiplatelet Agents for the Treatment and Prevention of Coronary Atherothrombosis. , 2017, Journal of the American College of Cardiology.
[5] Deepak L. Bhatt,et al. Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease , 2017, The New England journal of medicine.
[6] T. Maclagan. THE TREATMENT OF ACUTE RHEUMATISM BY SALICIN. , 1876 .
[7] C. Patrono,et al. Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. , 1982, The Journal of clinical investigation.
[8] L. Bolognese,et al. RANDOMISED TRIAL OF INTRAVENOUS STREPTOKINASE, ORAL ASPIRIN, BOTH, OR NEITHER AMONG 17 187 CASES OF SUSPECTED ACUTE MYOCARDIAL INFARCTION: ISIS-2 , 1988, The Lancet.
[9] R. de Caterina,et al. Aspirin therapy in primary cardiovascular disease prevention: a position paper of the European Society of Cardiology working group on thrombosis. , 2014, Journal of the American College of Cardiology.
[10] S. Rezkalla,et al. The Role of Aspirin in the Prevention of Cardiovascular Disease , 2014, Clinical Medicine & Research.
[11] K. Schrör,et al. Aspirin and lipid mediators in the cardiovascular system. , 2015, Prostaglandins & other lipid mediators.
[12] L. Craven. Experiences with aspirin (Acetylsalicylic acid) in the nonspecific prophylaxis of coronary thrombosis. , 1953, Mississippi Valley medical journal.
[13] R. de Caterina,et al. Selective inhibition of thromboxane-related platelet function by low-dose aspirin in patients after myocardial infarction. , 1985, The American journal of cardiology.
[14] K. Nicolaides,et al. Aspirin for the prevention of preterm and term preeclampsia: systematic review and metaanalysis , 2017, American journal of obstetrics and gynecology.
[15] R. Singer. ACETYLSALICYLIC ACID, A PROBABLE CAUSE FOR SECONDARY POST-TONSILLECTOMY HEMORRHAGE: A PRELIMINARY REPORT , 1945 .
[16] N. Cook,et al. Effects of aspirin on risks of vascular events and cancer according to bodyweight and dose: analysis of individual patient data from randomised trials , 2018, The Lancet.
[17] J. Curnow. THE TREATMENT OF ACUTE RHEUMATISM BY SALICIN. , 1876 .
[18] P. Glasziou. Aspirin after Myocardial Infarction , 1980, The Lancet.
[19] A. Jaffe,et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. , 2014, Circulation.
[20] C. Patrono,et al. Aspirin and Cancer. , 2016, Journal of the American College of Cardiology.
[21] W. Sneader,et al. The discovery of aspirin: a reappraisal , 2000, BMJ : British Medical Journal.
[22] C. Gerhardt. Untersuchungen über die wasserfreien organischen Säuren , 1853 .
[23] Craven Ll. Experiences with aspirin (Acetylsalicylic acid) in the nonspecific prophylaxis of coronary thrombosis. , 1953 .
[24] J. Sundström,et al. Low-Dose Aspirin Discontinuation and Risk of Cardiovascular Events: A Swedish Nationwide, Population-Based Cohort Study , 2017, Circulation.
[25] Ralph,et al. STUDIES ON THE HEMORRHAGIC SWEET CLOVER DISEASE IN THE GROUP* , 2003 .
[26] A. Korczyn,et al. Nonsteroidal anti-inflammatory drugs exposure and the central nervous system. , 2014, Handbook of clinical neurology.
[27] P. Rothwell,et al. Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials. , 2012, The Lancet. Oncology.
[28] M. LeWinter,et al. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration Cooperative Study. , 1983, The New England journal of medicine.
[29] The Coronis Collaborative Group. Swedish Aspirin Low-dose Trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischaemic events , 1991, The Lancet.
[30] C. Bryan. PAPYRUS EBERS. , 1931, Bulletin of the Medical Library Association.
[31] Jeroen J. Bax,et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). , 2011, European heart journal.
[32] D. Jack. One hundred years of aspirin , 1997, The Lancet.
[33] M. Packham,et al. THE EFFECT OF ACETYLSALICYLIC ACID ON PLATELET FUNCTION , 1968, The Journal of experimental medicine.
[34] H. Collier,et al. Analgesic antipyretic drugs as antagonists of bradykinin. , 1960, British journal of pharmacology and chemotherapy.
[35] P. Glasziou. Aspirin after myocardial infarction , 1989, Lancet.
[36] R. Amann,et al. Anti-inflammatory effects of aspirin and sodium salicylate. , 2002, European journal of pharmacology.
[37] Walter Sneader,et al. Drug Discovery (The History) , 2005 .
[38] L. Aledort,et al. The effect of salicylates on the hemostatic properties of platelets in man. , 1968, The Journal of clinical investigation.
[39] G. Born,et al. Aggregation of Blood Platelets by Adenosine Diphosphate and its Reversal , 1962, Nature.
[40] V. Tsatsaris,et al. Aspirin for Prevention of Preeclampsia , 2017, Drugs.
[41] P C Elwood,et al. A Randomized Controlled Trial of Acetyl Salicyclic Acid in the Secondary Prevention of Mortality from Myocardial Infarction , 1974, British medical journal.
[42] Suzanne G. Orchard,et al. Effect of Aspirin on Cardiovascular Events and Bleeding in the Healthy Elderly , 2018, The New England journal of medicine.
[43] W. Lands,et al. Purification of the cyclooxygenase that forms prostaglandins. Demonstration of two forms of iron in the holoenzyme. , 1976, The Journal of biological chemistry.
[44] G J Roth,et al. Acetylation of prostaglandin synthase by aspirin. , 1975, Proceedings of the National Academy of Sciences of the United States of America.
[45] J. Mann. Murder, Magic, and Medicine , 1992 .
[46] H. Dreser. Pharmakologisches über Aspirin (Acetylsalicylsäure) , 1899, Archiv für die gesamte Physiologie des Menschen und der Tiere.
[47] R. Collins,et al. Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus , 2018, The New England journal of medicine.
[48] P. Rothwell,et al. Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial , 2018, The Lancet.
[49] D. Keeling,et al. The aspirin story – from willow to wonder drug , 2017, British journal of haematology.
[50] J. Vane,et al. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. , 1971, Nature: New biology.
[51] Nicola Persico,et al. Aspirin versus Placebo in Pregnancies at High Risk for Preterm Preeclampsia , 2017, The New England journal of medicine.
[52] R. de Caterina,et al. Low-dose aspirin in patients recovering from myocardial infarction. Evidence for a selective inhibition of thromboxane-related platelet function. , 1985, European heart journal.
[53] P. Gibson. Aspirin in the treatment of vascular diseases. , 1949, Lancet.
[54] K. P. Link,et al. STUDIES ON THE HEMORRHAGIC SWEET CLOVER DISEASE XI. HYPOPROTHROMBINEMIA IN THE RAT INDUCED BY SALICYLIC ACID , 1943 .
[55] J. Vane,et al. Release of Additional Factors in Anaphylaxis and its Antagonism by Anti-inflammatory Drugs , 1969, Nature.
[56] J. Wood. From plant extract to molecular panacea: a commentary on Stone (1763) ‘An account of the success of the bark of the willow in the cure of the agues’ , 2015, Philosophical Transactions of the Royal Society B: Biological Sciences.
[57] Kirsten Bibbins-Domingo,et al. Aspirin Use for the Primary Prevention of Cardiovascular Disease and Colorectal Cancer: U.S. Preventive Services Task Force Recommendation Statement. , 2016, Annals of internal medicine.
[58] E. Hawk,et al. Beyond COX-1: the effects of aspirin on platelet biology and potential mechanisms of chemoprevention , 2017, Cancer and Metastasis Reviews.
[59] D. Atar,et al. ESC Guidelines for the Management of Acute Myocardial Infarction in Patients Presenting With ST-Segment Elevation , 2013 .
[60] P. Görög,et al. The biologic background to some therapeutic uses of aspirin. , 1983, The American journal of medicine.
[61] Boleslav Lichterman,et al. Aspirin: The Story of a Wonder Drug , 2004, BMJ : British Medical Journal.
[62] Effects of aspirin and non-aspirin nonsteroidal anti-inflammatory drugs on the incidence of recurrent colorectal adenomas: a systematic review with meta-analysis and trial sequential analysis of randomized clinical trials , 2017, BMC Cancer.
[63] C. Patrono,et al. Low-dose aspirin is a selective inhibitor of platelet cyclooxygenase activity in healthy subjects. , 1983, Advances in prostaglandin, thromboxane, and leukotriene research.
[64] J. Vane,et al. Aspirin and Other Salicylates , 1993 .
[65] R. Handin. The History of Antithrombotic Therapy: The Discovery of Heparin, the Vitamin K Antagonists, and the Utility of Aspirin. , 2016, Hematology/oncology clinics of North America.
[66] G. Pasero,et al. [The Italian contributions to the history of salicylates]. , 2011, Reumatismo.
[67] A. Algra,et al. A comparison of two doses of aspirin (30 mg vs. 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. , 1991, The New England journal of medicine.